Key Publications

 

Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, Schulz S, Hoppmann P, Hausleiter J, Tiroch K, Mehilli J, Schunkert H, Massberg S, Laugwitz KL, Sibbing D*, Kastrati A*. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thromb Haemost. 2014 Aug 28;112(6). [Epub ahead of print], *shared senior authorship

 

Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. 2014 Sep 2;64(9):863-71. doi: 10.1016/j.jacc.2014.05.049.

 

Sibbing D, Massberg S. Dual antiplatelet treatment after stenting: is longer better? Lancet. 2014 Jul 15. pii: S0140-6736(14)60768-6. doi:10.1016/S0140-6736(14)60768-6. [Epub ahead of print]

 

Sibbing D, Massberg S. There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients. Thromb Haemost. 2014 Jul 3;112(1):10-1. doi: 10.1160/TH14-03-0216. Epub 2014 May 8.

 

Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR HPR registry. Thromb Haemost. 2014 Aug;112(2):342-51. doi: 10.1160/TH13-10-0874. Epub 2014 Apr 10.

 

Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, Hadamitzky M, Schunkert H, Laugwitz KL, Massberg S, Kastrati A, Sibbing D. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets. 2014 Jan 16. [Epub ahead of print]

 

Straub N, Beivers A, Lenk E, Aradi D, Sibbing D. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb Haemost. 2014 Feb;111(2):290-9. doi: 10.1160/TH13-08-0679. Epub 2013 Oct 24.

 

Gross L, Massberg S, Sibbing D. [Cardiological diseases]. Internist (Berl). 2013 Oct;54(10):1171-84. doi: 10.1007/s00108-013-3294-8. German.

 

Sibbing D, Gross L, Orban M, Massberg S. Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition? JACC Cardiovasc Interv. 2013 Aug;6(8):864-6. doi: 10.1016/j.jcin.2013.06.002.

 

Orban M, Sibbing D. Platelet function testing in patients with acute coronary syndrome. J Cardiovasc Transl Res. 2013 Jun;6(3):371-7. doi: 10.1007/s12265-013-9450-7. Epub 2013 Feb 9.

 

Bernlochner I, Mayer K, Morath T, Orban M, Schulz S, Schömig A, Braun S, Kastrati A, Sibbing D. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.  Thromb Haemost. 2013 Mar;109(3):517-24. doi: 10.1160/TH12-08-0552. Epub 2013 Jan 17.

 

Sibbing D, Orban M, Massberg S. Potent P2Y12 receptor inhibitors in patients  with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Hamostaseologie. 2013;33(1):9-15. doi: 10.5482/HAMO-12-12-0022. Epub 2013 Jan 8.

 

Sibbing D, Bernlochner I, Schulz S, Massberg S, Schömig A, Mehilli J, Kastrati A. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol. 2012 Jul 31;60(5):369-77. doi: 10.1016/j.jacc.2012.02.044. Epub 2012 Jun 6.

 

Orban M, Riegger J, Joner M, Tada T, Okrojek R, Hausleiter J, Kastrati A, Massberg S, Sibbing D. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets. 2012;23(5):395-8. doi: 10.3109/09537104.2012.691189. Epub 2012 Jun 6. Erratum in: Platelets. 2012;23(5):398. PubMed PMID: 22671583.

 

Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011 Sep;162(3):518-26.e5. doi: 10.1016/j.ahj.2011.06.005. Epub 2011 Aug 11.

 

Orban M, Byrne RA, Hausleiter J, Laugwitz KL, Sibbing D. Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thromb Haemost. 2011 Sep;106(3):555-8. doi: 10.1160/TH11-04-0267. Epub 2011 Jul 4.

 

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

 

Sibbing D, Pfeufer A, Perisic T, Mannes AM, Fritz-Wolf K, Unwin S, Sinner MF, Gieger C, Gloeckner CJ, Wichmann HE, Kremmer E, Schäfer Z, Walch A, Hinterseer M, Näbauer M, Kääb S, Kastrati A, Schömig A, Meitinger T, Bornkamm GW, Conrad M, von Beckerath N. Mutations in the mitochondrial thioredoxin reductase gene TXNRD2cause dilated cardiomyopathy. Eur Heart J. 2011 May;32(9):1121-33. doi:10.1093/eurheartj/ehq507. Epub 2011 Jan 18.

 

Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010 Jul 20;56(4):317-8. doi: 10.1016/j.jacc.2010.03.048.

 

Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Seyfarth M, Kastrati A,  von Beckerath N, Schömig A. A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment. J Am Coll Cardiol. 2010 Feb 9;55(6):558-65. doi: 10.1016/j.jacc.2009.09.038.

 

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

 

Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction? Lancet. 2009 Sep 19;374(9694):952-4. doi: 10.1016/S0140-6736(09)61562-2. Epub 2009 Aug 31.

 

Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. Doi 10.1016/j.jacc.2008.11.030.

 

Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009 Apr;30(8):916-22. doi: 10.1093/eurheartj/ehp041. Epub 2009 Feb